New Monograph Describes Racial/Ethnic Cancer Patterns in the US

Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Neil M. Iyengar, MD, highlighted the recent T-DXd and Dato-DXd approvals in breast cancer.

Viviana Cortiana, MS4;Yan Leyfman, MD

Maximizing Safe Resection in High-Grade Gliomas

Advances in next-generation sequencing and gene expression are reshaping T-cell lymphoma classification and the use of targeted therapies.

Ariana Pelosci

Reviewing Real-World Use of Beti-Cel in Transfusion-Dependent β-Thalassemia

Jennifer Moliterno, MD, FAANS, discusses current neurosurgical strategies for newly diagnosed high-grade gliomas.

Therapies like betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.

Nora M. Gibson, MD, MSCE;Taha Al-Juhaishi, MD

May 5th 2025

Phase 2B Trial for Cancer Vaccine in Newly Diagnosed Glioblastoma Will Continue

Therapies such as betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.

Russ Conroy

FDA Grants THE001 Orphan Drug Designation for Soft Tissue Sarcomas

An independent data safety monitoring board determines that the phase 2b SURVIVE trial in newly diagnosed glioblastoma may continue without modification.

The FDA designation follows an orphan drug designation granted by the European Medicines Agency for THE001 in patients with soft tissue sarcoma.

Roman Fabbricatore

Recent ADC Approvals and Their Impact on the Breast Cancer Space

The FDA designation follows an orphan drug designation granted by the European Medicines Agency for THE001 in patients with soft tissue sarcoma.

Related Content

Neil M. Iyengar, MD

Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Neil M. Iyengar, MD, highlighted the recent T-DXd and Dato-DXd approvals in breast cancer.

Viviana Cortiana, MS4;Yan Leyfman, MD

Maximizing Safe Resection in High-Grade Gliomas

Advances in next-generation sequencing and gene expression are reshaping T-cell lymphoma classification and the use of targeted therapies.

Ariana Pelosci

Reviewing Real-World Use of Beti-Cel in Transfusion-Dependent β-Thalassemia

Jennifer Moliterno, MD, FAANS, discusses current neurosurgical strategies for newly diagnosed high-grade gliomas.

Nora M. Gibson, MD, MSCE;Taha Al-Juhaishi, MD

May 5th 2025

Phase 2B Trial for Cancer Vaccine in Newly Diagnosed Glioblastoma Will Continue

Therapies such as betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.

Russ Conroy

FDA Grants THE001 Orphan Drug Designation for Soft Tissue Sarcomas

An independent data safety monitoring board determines that the phase 2b SURVIVE trial in newly diagnosed glioblastoma may continue without modification.

Roman Fabbricatore